{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:42:53Z","timestamp":1780360973691,"version":"3.54.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:21:42Z","timestamp":1698150102000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas"],"prefix":"10.1016","volume":"24","author":[{"given":"Jackson S.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2023.10.007_bib0001","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.10.007_bib0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.007_bib0003","article-title":"Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.007_bib0004","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2022-164988","article-title":"Patterns of care and clinical outcomes in peripheral T-cell lymphomas: the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (LEO-MER) prospective cohort study","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0005","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2023.10.007_bib0006","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.10.007_bib0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of peripheral T-cell lymphoma diagnostic workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2023.10.007_bib0008","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.clml.2023.10.007_bib0009","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3324\/haematol.2019.238766","article-title":"Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target","volume":"106","author":"Larose","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0011","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41379-021-00937-0","article-title":"Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up","volume":"35","author":"Vega","year":"2022","journal-title":"Mod Pathol"},{"issue":"10168","key":"10.1016\/j.clml.2023.10.007_bib0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2023.10.007_bib0013","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK\u00a0+\u00a0ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.007_bib0014","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2019-122781","article-title":"An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-Cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant","volume":"134","author":"Savage","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.10.007_bib0015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of peripheral T-cell lymphomas and the role of transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.clml.2023.10.007_bib0016","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0017","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3324\/haematol.2022.281442","article-title":"ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study","volume":"108","author":"Sibon","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0018","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0020","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.10.007_bib0021","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.10.007_bib0022","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.10.007_bib0024","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0026","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2021.03.002","article-title":"Clinicopathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis: RHOA mutations in AITL","volume":"21","author":"Nguyen","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2023.10.007_bib0027","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0028","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.3390\/curroncol28060456","article-title":"Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma","volume":"28","author":"Mohammed Saleh","year":"2021","journal-title":"Curr Oncol"},{"issue":"21","key":"10.1016\/j.clml.2023.10.007_bib0029","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.10.007_bib0030","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0031","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.clml.2023.10.007_bib0032","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.clml.2023.10.007_bib0033","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.10.007_bib0034","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.clml.2023.10.007_bib0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0036","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.18885","article-title":"Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma","volume":"202","author":"Stuver","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0037","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0038","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0039","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.10.007_bib0040","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.clml.2023.10.007_bib0041","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2023.10.007_bib0042","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.10.007_bib0043","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"suppl 5","key":"10.1016\/j.clml.2023.10.007_bib0044","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.10.007_bib0045","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0046","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0047","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0048","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.clml.2023.10.007_bib0049","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.007_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2021-151105","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0051","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.10.007_bib0052","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Mehta-Shah","year":"2021","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.clml.2023.10.007_bib0053","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.007_bib0054","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.10.007_bib0055","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/JCO.2021.39.15_suppl.7533","article-title":"Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma","volume":"39","author":"Khan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.10.007_bib0056","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0057","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.007_bib0058","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral azacytidine in patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: final analysis of the oracle phase III study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.10.007_bib0059","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2021011679","article-title":"Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL","volume":"139","author":"Martin","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.10.007_bib0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.clml.2023.10.007_bib0061","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jgo.2021.10.003","volume":"13","author":"Brem","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"18","key":"10.1016\/j.clml.2023.10.007_bib0062","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.007_bib0063","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: results of an interim analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.007_bib0064","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/01.HS9.0000847552.42271.7c","article-title":"P1172: duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: updated expansion phase analysis","volume":"6","author":"Zinzani","year":"2022","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.clml.2023.10.007_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"issue":"S2","key":"10.1016\/j.clml.2023.10.007_bib0066","first-page":"404","article-title":"Azacytidine and decitabine exhibit differential effects on cytotoxicity and methylation and exhibit class synergy with HDACi in models of PTCL","volume":"130","author":"Scotto","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.10.007_bib0067","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2023.10.007_bib0068","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.25228","article-title":"Duvelisib, an oral dual PI3K-delta, gamma inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study","volume":"93","author":"Flinn","year":"2018","journal-title":"Am J Hematol"},{"issue":"S2","key":"10.1016\/j.clml.2023.10.007_bib0069","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hon.3164_367","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial expansion phase: outcomes by baseline histology","volume":"41","author":"Mehta-Shah","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.007_bib0070","series-title":"Presented at: European Hematology Association","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology","author":"Mehta-Shah","year":"2023"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0071","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clml.2023.10.007_bib0072","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0073","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase ii study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0074","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","article-title":"How we treat NK\/T-cell lymphomas","volume":"15","author":"Tse","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0075","first-page":"696","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma","volume":"379","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.10.007_bib0076","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-319-99716-2_3","article-title":"Tumor Microenvironment in T-Cell Lymphomas","volume":"176","author":"Bennani","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"6","key":"10.1016\/j.clml.2023.10.007_bib0077","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2023.10.007_bib0078","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s43018-023-00635-7","article-title":"PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma","volume":"4","author":"Wartewig","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2023.10.007_bib0079","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2022-168979","article-title":"Results from a phase I trial using nivolumab in combination with dose adjusted EPOCH in newly diagnosed peripheral T-cell lymphomas","volume":"140","author":"Haverkos","year":"2022","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2023.10.007_bib0080","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.10.007_bib0081","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdv010","article-title":"Utility of \u00b9\u2078fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Horwitz","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.10.007_bib0082","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0083","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0084","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.10.007_bib0085","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.10.007_bib0086","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: a review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.007_bib0087","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1182\/blood-2021-148768","article-title":"End of treatment peripheral blood TCR evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas","volume":"138","author":"Mehta-Shah","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.10.007_bib0088","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1200\/JCO.2023.41.16_suppl.7563","article-title":"A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant","volume":"41","author":"Foley","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2023.10.007_bib0089","first-page":"4198","article-title":"Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2023.10.007_bib0090","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.10.007_bib0091","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18824","article-title":"Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma","volume":"202","author":"Wei","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.clml.2023.10.007_bib0092","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.10.007_bib0093","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood.2021013568","article-title":"Whole-genome landscape of adult T-cell leukemia\/lymphoma","volume":"139","author":"Kogure","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.10.007_bib0094","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood.V80.12.3205.3205","article-title":"Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia\/lymphoma shows frequent p53 mutations","volume":"80","author":"Cesarman","year":"1992","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.10.007_bib0095","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.clml.2023.10.007_bib0096","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.clml.2023.10.007_bib0097","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.10.007_bib0098","doi-asserted-by":"crossref","first-page":"e4420","DOI":"10.1371\/journal.pone.0004420","article-title":"Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma","volume":"4","author":"Ratner","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clml.2023.10.007_bib0099","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1038\/bcj.2016.21","article-title":"Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma","volume":"6","author":"Ratner","year":"2016","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2023.10.007_bib0100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.10.007_bib0101","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2023.10.007_bib0102","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.10.007_bib0103","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2023.41.16_suppl.7504","article-title":"A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia\/lymphoma","volume":"41","author":"Choi","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:14Z","timestamp":1761871394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023021511"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}